Chinook Therapeutics CEO says Novartis acquisition will be good for patients

KDNYDelisted Stock  USD 39.25  0.20  0.51%   
Slightly above 53% of Chinook Therapeutics' investor base is interested to short. The analysis of current outlook of investing in Chinook Therapeutics suggests that many traders are impartial regarding Chinook Therapeutics' prospects. Chinook Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Chinook Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Chinook CEO Eric Dobmeier spent 15 years at Seagen earlier in his career.

Read at bizjournals.com
bizjournals News
  

Chinook Therapeutics Fundamental Analysis

We analyze Chinook Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chinook Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chinook Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Earnings To Growth

Price To Earnings To Growth Comparative Analysis

Chinook Therapeutics is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

Chinook Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Chinook Therapeutics stock to make a market-neutral strategy. Peer analysis of Chinook Therapeutics could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics with similar companies.

Peers

Chinook Therapeutics Related Equities

PLRXPliant Therapeutics   2.00   
0%
100.0%
DAWNDay One   1.53   
0%
76.0%
VTYXVentyx Biosciences   1.13   
0%
56.0%
TVTXTravere Therapeutics   0.59   
0%
29.0%
PCVXVaxcyte   0.38   
0%
19.0%
NUVLNuvalent   0.08   
4.0%
0%
ASNDAscendis Pharma   0.18   
9.0%
0%
KALVKalvista Pharmaceuticals   0.30   
15.0%
0%
SWTXSpringWorks Therapeutics   0.60   
30.0%
0%
RNAAvidity Biosciences   0.69   
34.0%
0%
CRNXCrinetics Pharmaceuticals   0.81   
40.0%
0%
ACLXArcellx   1.12   
56.0%
0%
KURAKura Oncology   1.16   
57.0%
0%
RVMDRevolution Medicines   1.25   
62.0%
0%
VRDNViridian Therapeutics   1.46   
73.0%
0%
GPCRStructure Therapeutics   1.78   
89.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Consideration for investing in Chinook Stock

If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Valuation
Check real value of public entities based on technical and fundamental data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories